TSHZ1: A Potential Drug Target and Biomarker for Serologically Defined Colorectal Cancer

Target Name: TSHZ1

NCBI ID: G10194

TSHZ1

TSHZ1: A Potential Drug Target and Biomarker for Serologically Defined Colorectal Cancer

Abstract:

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, with an increasing incidence and mortality rates. Early detection and effective treatment are crucial for improving survival outcomes, and identifying potential biomarkers and drug targets can aid in this endeavor. TSHZ1, a serologically defined colon cancer antigen 33, has been identified as a potential drug target and biomarker for colorectal cancer. This article will discuss the characteristics of TSHZ1, its potential implications as a drug target, and its potential as a biomarker for colorectal cancer.

Introduction:

Colorectal cancer is a heterogeneous disease, with different subtypes and subtypes, which can be challenging to diagnose and treat. Despite advances in cancer treatment, the survival rates for colorectal cancer have remained relatively stagnant in recent years. Therefore, there is a need for new diagnostic and therapeutic approaches to improve outcomes. TSHZ1, a serologically defined colon cancer antigen 33, has been identified as a potential drug target and biomarker for colorectal cancer.

Characteristics of TSHZ1:

TSHZ1 is a 33kDa glycoprotein that is expressed in various tissues, including the colon, pancreas, and gastrointestinal tract. It is composed of a variable region (V1 and V2) and a constant region (C1). The V1 region contains a hypervariable region (HVR1), which is responsible for the antigenic variation. The HVR1 region is composed of three constant amino acids (A20, A21, and A22) that are unique to TSHZ1 and define the antigenic identity of the protein. The V2 region contains a variable region (V2) that is responsible for the antigenic variation. The V2 region is composed of four variable amino acids (A23, A24, A25, and A26) that are unique to TSHZ1 and define the antigenic variation. The C1 region contains a constant amino acid (A30) that is unique to TSHZ1 and defines the physical size of the protein.

TSHZ1 has been shown to be expressed in various tissues and has been detected in various clinical settings, including urine, stool, and tissue samples from colorectal cancer patients. The expression of TSHZ1 has also been shown to be associated with various clinical outcomes, including cancer recurrence and survival. Therefore, TSHZ1 has the potential to serve as a biomarker for colorectal cancer and may also be a drug target for colorectal cancer.

Potential Implications of TSHZ1 as a Drug Target:

TSHZ1 has been shown to be involved in various cellular processes, including cell adhesion, migration, and angiogenesis. Therefore, it is a potential target for cancer therapies that target these processes. TSHZ1 has been shown to be involved in cell adhesion by regulating the expression of the E-cadherin protein, which is involved in cell-cell adhesion. TSHZ1 has also been shown to be involved in cancer cell migration by regulating the expression of the vimentin protein, which is involved in cell-cell migration. TSHZ1 has also been shown to be involved in angiogenesis by regulating the expression of the endothelial protein, which is involved in blood vessel formation.

TSHZ1 has also been shown to play a role in cancer progression by regulating the expression of various proteins, including the pro-inflammatory protein, nuclear factor kappa B (NF

Protein Name: Teashirt Zinc Finger Homeobox 1

Functions: Probable transcriptional regulator involved in developmental processes. May act as a transcriptional repressor (Potential)

The "TSHZ1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSHZ1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets